Valuation: Agenus Inc.

Market Cap 336M 292M 272M 249M 471M 32.04B 478M 3.2B 1.26B 15.95B 1.26B 1.23B 53.49B P/E 2026 *
8.82x
P/E 2027 * -46.9x
Enterprise Value 336M 292M 272M 249M 471M 32.04B 478M 3.2B 1.26B 15.95B 1.26B 1.23B 53.49B EV / Sales 2026 *
2.45x
EV / Sales 2027 * 2.44x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day-5.18%
1 week+25.42%
1 month+145.10%
3 months+91.82%
6 months+164.08%
Current year+138.85%
1 week 5.87
Extreme 5.87
7.99
1 month 3.1
Extreme 3.1
8.7
Current year 2.71
Extreme 2.71
8.7
1 year 2.71
Extreme 2.71
8.7
3 years 1.38
Extreme 1.38
32
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 30/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/10/2021
Director TitleAgeSince
Chairman 73 03/11/2010
Director/Board Member 68 07/03/2007
Director/Board Member 68 06/12/2006
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Free

Chief Executive Officer

4,852 0.0117%
01/07/26 Free

Director

2,268 0.0054%
01/07/26 Free

Director

8,547 0.0205%
Change 5-day change 1-year change 3-year change Capi.($)
-5.18%+25.42%+35.87%-75.33% 336M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+403.17%+614.40% 39.87B
-1.16%+12.96%+26.45%+5.03% 38.68B
-1.88%-3.03%+4.94%+47.52% 35.13B
-1.74%+5.12%+9.58%+46.02% 29.79B
-2.85%-3.92% - - 16.08B
-0.21%-4.04%+35.09%+127.95% 16.11B
-0.64%+2.65%+1.25%+8.92% 13.61B
-1.19%-1.32%-3.32%-34.94% 12.62B
Average -1.87%+3.49%+56.81%+83.43% 25.08B
Weighted average by Cap. -1.60%+2.07%+76.81%+127.81%

Financials

2026 *2027 *
Net sales 137M 119M 111M 102M 192M 13.06B 195M 1.3B 512M 6.5B 514M 502M 21.8B 138M 120M 111M 102M 193M 13.14B 196M 1.31B 515M 6.54B 517M 505M 21.93B
Net income 45.4M 39.47M 36.73M 33.73M 63.69M 4.33B 64.68M 433M 170M 2.16B 171M 167M 7.23B -17.8M -15.47M -14.4M -13.22M -24.97M -1.7B -25.36M -170M -66.63M -846M -66.85M -65.38M -2.84B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
31/07/26 US$7.500 -5.18% 1,573,848
30/07/26 US$7.910 +19.31% 3,002,899
29/07/26 US$6.630 +0.45% 1,857,226
28/07/26 US$6.600 +7.67% 2,785,167
27/07/26 US$6.130 +2.51% 1,234,481
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.500USD
Average target price
22.00USD
Spread / Average Target
+193.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock